Synaptogenix to Present Abstract on Benefits of Candidate in Severe Alzheimer's

 Phase 2 Bryostatin-1 Severe Cohort secondary and exploratory endpoint data selected by independent committee for presentation

 Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that an abstract featuring secondary endpoint data of its National Institutes of Health (NIH) sponsored Phase 2 Bryostatin-1 trial was accepted for presentation at the 11th International Brain Research Organization (IBRO) World Congress of Neuroscience to be held in September 2023 in Spain.

In the recently completed Phase 2 clinical trial of Bryostatin-1, two cohorts were studied: a Moderate Cohort, with MMSE* scores of 15-18, and a Severe Cohort, with MMSE scores of 10-14.  All patients were randomized with respect to treatment groups, with safety checked by an independent Data Safety Monitoring Board (DSMB). While Moderate Cohort patients showed no significant benefit, for patients of the Severe Cohort, representing the patient population with the most advanced Alzheimer's disease (AD), nearly all pre-specified secondary endpoints were achieved with statistical significance.  Data also showed statistical significance in exploratory secondary endpoints for this Severe Cohort (MMSE 10-14 stratum), and post hoc analysis was positive. Statistical significance in these analyses was measured by patients' Severe Impairment Battery* (SIB) changes from baseline for the Bryostatin-1 treatment group compared with the placebo group patients.

https://finance.yahoo.com/news/synaptogenix-abstract-highlighting-bryostatin-1-130000474.html